
January 2025: The number of pending actions in the GLP-1 RA MDL continues to grow, with 1,331 actions now pending.
Active case
Trulicity® lawsuits address severe health complications believed to stem from taking the type 2 diabetes medication. These issues include gastrointestinal problems, blood clots and vision loss.
Connect with an attorneyActive case
Trulicity® (dulaglutide) lawsuits claim that drug manufacturer Eli Lilly knew or should have known that its product may cause serious health problems but failed to warn consumers about dangerous side effects. Plaintiffs are seeking compensation for injuries related to taking Trulicity, such as gastroparesis and intestinal blockage.
Lawsuits against Eli Lilly allege the manufacturer was aware or should’ve been aware of dangerous side effects associated with Trulicity (dulaglutide) and other GLP-1 RA drugs. Eli Lilly failed to warn consumers, including many who now suffer from severe health conditions, plaintiffs argue.
The Trulicity® lawsuit is a part of a MDL that includes several other type 2 diabetes medications and prescription weight-loss medications. Eli Lilly also faces litigation concerning Mounjaro® and Zepbound® — brand names for the drug tirzepatide.
In addition, drug manufacturer Novo Nordisk faces lawsuits over injuries that users allege were caused by its GLP-1 medications, including Ozempic® and Wegovy® (both generically called semaglutide) and their predecessors.
The Trulicity MDL is a mass tort litigation lawsuit. Plaintiffs have brought claims against Eli Lilly and Novo Nordisk for injuries allegedly caused by GLP-1 RA medications.
The MDL names several drugs, including Trulicity, Mounjaro, Ozempic and Wegovy. The lawsuits claim the medications lead to gastrointestinal injuries and other severe side effects. The lawsuits also allege that Eli Lilly and Novo Nordisk didn’t warn patients or prescribing doctors about dangerous side effects. Additionally, the companies are accused of making false and misleading statements about the medications’ safety.
Motley Rice is among the law firms that argued for the creation of the GLP-1 RA multidistrict litigation, which originated in February 2024. The case was initially assigned to U.S. District Judge Gene E.K. Pratter. However, Pratter unexpectedly died in May. In June, U.S. District Judge Karen Marston was named Pratter’s replacement.
As of January 2, 2025, the MDL currently includes more than 1,331 pending actions. Lawyers for the cases expect the lawsuit to eventually contain more than 10,000 claims. Litigation is still in the beginning stages, and new plaintiffs can still join the lawsuit. As of now, all related cases have yet to go to trial or be resolved.
When many plaintiffs have the same complaints against the same defendant, multidistrict litigation (MDL) can lessen the pre-trial burden. With an MDL, pretrial proceedings and discovery happen in one district court after which cases go back to their original district for trial if not settled. Each plaintiff has a lawyer, and each claim may receive its own verdict.
MDLs can be advantageous because they streamline the legal process for both parties and the courts.
No Trulicity class action lawsuits have been filed. Instead, GLP-1 RA medication personal injury cases are being consolidated into an MDL.
Class actions and MDLs differ. With a class action lawsuit, a lawsuit is filed by one or multiple plaintiffs on behalf of a “class” of similarly harmed claimants. Any judgment in the case applies to the entire class, and plaintiffs can’t bring individual lawsuits.
Trulicity and other GLP-1 RA lawsuits have been brought by plaintiffs who’ve suffered serious and life-altering injuries.
In one such case, a female plaintiff suffered severe gastrointestinal injuries after taking Ozempic and then Mounjaro to treat type 2 diabetes. The plaintiff experienced severe stomach pain and vomiting, leading to several emergency room visits and a hospitalization.
In another lawsuit, Motley Rice filed a claim on behalf of a woman who was diagnosed with gastroparesis after taking Wegovy for approximately six months. The woman’s diagnosis came after she was hospitalized for being unable to tolerate food or drink. She continues to have adverse health effects in her daily life.
Many other plaintiffs have filed lawsuits for illnesses suffered in connection with GLP-1 RA drugs. The lawsuits allege that:
Complete this form or call 1.800.768.4026 to contact attorney Sara Couch for more information or to discuss a potential Trulicity claim.
Approved by the U.S. Food and Drug Administration (FDA) in 2014, Trulicity is a GLP-1 RA medication used to treat type 2 diabetes. In 2020, the FDA also approved the use of Trulicity to reduce cardiovascular events in adults, like stroke and heart attack.
The FDA hasn’t approved Trulicity and Ozempic for weight loss, though some doctors prescribe them for this off-label use. The FDA has approved other GLP-1 RAs, including Wegovy and Saxenda® (liraglutide) for weight reduction.
Trulicity and other GLP-1 RAs work by mimicking the body’s naturally produced GLP-1 hormone. GLP-1 RA drugs trigger increased insulin production, stop the release of sugar (glucose) into the bloodstream, slow stomach emptying and cause feelings of fullness after eating.
Most GLP-1 RA drugs are injectable medications. Some require daily injections, while others require weekly or twice weekly injections. Trulicity is a once-weekly injectable.
Plaintiffs in the Trulicity lawsuit claim they have suffered severe side effects caused by GLP-1 RAs. Many of the medical problems experienced by Trulicity users aren’t on the drug’s warning label or were added after patients started taking the medication.
Studies suggest that taking Trulicity and other GLP-1 agonists increases the risk of nonarteritic anterior ischemic optic neuropathy (NAION) — a type of optic nerve damage and the leading cause of blindness in adults. Trulicity’s warning label doesn’t mention NAION.
The label does warn about the risk of developing diabetic retinopathy (the growth of abnormal blood vessels in the retina). The warning for this condition was not added until February 2020.
Trulicity’s label doesn’t warn about blood clots. However, some users allege that GLP-1 RA drugs, like Ozempic and Wegovy, cause clots and related health conditions that include:
Studies suggest that taking GLP-1 RAs significantly increases the risk of gallbladder or biliary diseases. Biliary diseases affect the bile ducts, gallbladder, and systems that produce and transport bile. Symptoms of biliary disease include jaundice (yellowing of the eyes and skin), abdominal pain, fever, fatigue, nausea and vomiting. Trulicity’s label lacks a warning of these dangers.
An inflammation of the stomach and intestines, gastroenteritis causes pain, diarrhea and vomiting. Once again, this side effect isn’t included on Trulicity’s label, but GLP-1 RA lawsuit plaintiffs complain of experiencing this type of gastrointestinal distress while taking these medications.
Trulicity and other GLP-1 RAs slow the body’s ability to empty the stomach, potentially causing gastroparesis. No cure has been found for this medical condition, which can lead to dehydration, malnutrition and a decreased quality of life. Gastroparesis can also lead to a blockage of undigested food called a bezoar, which can be life-threatening.
Trulicity’s label states under Drug Interactions that it produces delayed gastric emptying, but the label doesn’t warn against the risk of gastroparesis.
Ileus is the inability of the intestines to push food and waste out of the body. This condition can lead to intestinal obstruction. Severe complications of ileus and intestinal obstruction include tissue death, infection of the abdominal cavity and perforation of the intestinal wall.
Studies find that patients taking GLP-1 RAs have more than a three-fold increase in intestinal obstruction rate. Yet, Trulicity’s label doesn’t mention ileus or intestinal obstruction as a potential side effect.
The American Society of Anesthesiologists warns those taking GLP-1 RAs to avoid taking the medicine before surgery. This warning is due to an increased risk of regurgitating and aspirating food in the airways and lungs. Trulicity’s label doesn’t mention this danger.
Among the many side effects that are included on Trulicity’s Warnings and Precautions label are:
01.02.25
January 2025: The number of pending actions in the GLP-1 RA MDL continues to grow, with 1,331 actions now pending.
08.01.24
The court established time and expense protocols and a common benefit fund for the GLP-1 RA multidistrict litigation. The court’s case management order outlined how plaintiffs and their attorneys involved in diabetes and weight-loss drug multidistrict litigation (MDL) would share the burden of legal services and expenses.
07.01.24
New research came to light associating GLP-1 RA medications with vision loss and blindness. New lawsuits were filed in the MDL over injuries believed to be caused by GLP-1 receptor agonist (RA) drugs, bringing the number of cases to more than 100.
06.01.24
U.S. District Judge Karen Marston was appointed to preside over the cases. The appointment was necessary due to the unexpected death of U.S. District Judge Gene E.K. Pratter on May 17.
05.01.24
Attorney Jonathan Orent of Motley Rice was named co-lead counsel for the GLP-1 RA multidistrict litigation’s Plaintiff’s Executive Committee (PEC). Motley Rice attorney Sara Couch was named Chair of Marketing Discovery for the PEC.
02.01.24
Lawyers, including attorney Jonathan Orent, successfully argued for assigning the diabetes and weight-loss drug MDL to the Eastern District of Pennsylvania.
On and off-label side effects associated with Trulicity and other GLP-1 RA medications include acute kidney injury, pancreatitis and digestive problems. Some of the health problems believed to stem from Trulicity intake may result in permanent and life-altering injuries and death.
On-label side effects of Trulicity include:
Side effects not listed on Trulicity’s label include:
Trulicity may not be safe for all users, as some patients have experienced severe and deadly side effects.
Trulicity, Ozempic, Wegovy, Mounjaro and other GLP-1 agonists have received FDA approval for the treatment of type 2 diabetes or weight loss. Approval doesn’t mean the drugs are side-effect-free, though. Some users have experienced severe symptoms.
Anyone considering using a GLP-1 RA should consult their healthcare provider before taking the drug. Patients currently taking these medications should not stop their usage without first consulting their physician.
Injured parties can file a Trulicity lawsuit by contacting Motley Rice to learn more about their legal options. Cases are currently being consolidated in U.S. District Court for the Eastern District of Pennsylvania. As of January 2, 2025, more than 1,331 actions are pending, but lawyers expect to add as many as 10,000 claims.
You may be eligible for the MDL if:
If you have questions about the Trulicity MDL and whether you qualify to seek compensation for medical expenses or lost wages, reach out to an attorney at Motley Rice today.
Motley Rice attorneys have been litigating medical drug litigation for decades. Our attorneys have represented thousands of clients harmed by dangerous medications and medical devices. With our legal and scientific knowledge, we can help you navigate even the most complex cases. We will use our resources and case experiences to pursue justice for you or your loved one.
Learn more about our medical drug litigation experience.
Do not stop taking a prescribed medication without first consulting with your doctor. Discontinuing a prescribed medication without your doctor's advice can result in injury or death. Trulicity, Ozempic, Wegovy, Mounjaro Saxenda and Zepbound remain approved by the U.S. Food and Drug Administration.
Important Trulicity lawsuit updates
Key takeaways about Trulicity lawsuits
Why is there a lawsuit against Trulicity?
What is multidistrict litigation?
Is there a Trulicity class action lawsuit?
What is Trulicity?
Injuries named in Trulicity side effects lawsuits
Listed Trulicity side effects
Trulicity lawsuit updates timeline
Frequently asked questions (FAQs) about Trulicity
Our medical drug litigation experience
Call us or fill out our online form with the details of your potential case.
Our team reviews your information to assess your potential case.
Talk with us about next steps.